Antitussive compositions comprising memantine

Abstract

Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.

1 - 42 . (canceled) 
     
     
         43 . An antitussive oral formulation comprising: memantine, or a pharmaceutically acceptable salt thereof; an alkalinizing agent; menthol; and one or more excipients. 
     
     
         44 . The antitussive oral formulation of  claim 43 , wherein the memantine is in an amount of about 3 mg to about 35 mg. 
     
     
         45 . The antitussive oral formulation of  claim 43 , wherein the alkalinizing agent comprises sodium carbonate and sodium bicarbonate. 
     
     
         46 . The antitussive oral formulation of  claim 45 , wherein the sodium carbonate and sodium bicarbonate are at a weight ratio of about 1:1 to about 1:10, in an amount sufficient to raise the pH of the oral cavity. 
     
     
         47 . The antitussive oral formulation of  claim 43 , wherein the excipients are selected from one or more from the group consisting of a binder, one or more sugar or sugar substitutes, a filler, a disintegrant, and a lubricant. 
     
     
         48 . The antitussive oral formulation of  claim 43 , wherein the excipients comprise microcrystalline cellulose, magnesium stearate, starch and mannitol. 
     
     
         49 . The antitussive oral formulation of  claim 43 , wherein the excipients comprise xylitol, erythritol, and eucalyptus oil. 
     
     
         50 . The antitussive oral formulation of  claim 43 , wherein the antitussive oral formulation is substantially free of pharmaceutically active ingredients other than memantine and menthol. 
     
     
         51 . The antitussive oral formulation of  claim 43 , further comprising one or more additional pharmaceutically active ingredients selected from the group consisting of antitussives other than memantine, expectorants, mucolytics, decongestants, nasal decongestants, first generation antihistamines, antihistamines, opioid analgesics, non-opiate analgesics, antipyretics, and combinations thereof. 
     
     
         52 . The antitussive oral formulation of  claim 51 , wherein the one or more additional pharmaceutically active ingredients are selected from the group consisting of guaifenesin, ambroxol, a first generation antihistamine, and combinations thereof. 
     
     
         53 . The antitussive oral formulation of  claim 52 , wherein the one or more additional pharmaceutically active ingredient is guaifenesin. 
     
     
         54 . The antitussive oral formulation of  claim 52 , wherein the one or more additional pharmaceutically active ingredients comprise a first generation antihistamine. 
     
     
         55 . The antitussive oral formulation of  claim 43 , wherein the total weight of the antitussive oral formulation is up to about 2.8 grams. 
     
     
         56 . The antitussive oral formulation of  claim 43 , wherein the alkalizing agent is selected from one or more of the group consisting of magnesium oxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, ammonium carbonate, sodium phosphate tribasic and sodium phosphate dibasic. 
     
     
         57 . The antitussive oral formulation of  claim 43 , wherein after a single buccal or sublingual administration to a patient, the antitussive oral formulation provides a memantine T max  ranging from about 15 minutes to about 5.5 hours. 
     
     
         58 . The antitussive oral formulation of  claim 43 , wherein after a single buccal or sublingual single administration to a patient, the antitussive oral formulation provides: a memantine T max  ranging from about 15 minutes to about 1.5 hours. 
     
     
         59 . The antitussive oral formulation of  claim 43 , wherein after a single buccal or sublingual administration to a patient, the antitussive oral formulation provides: a memantine T max  ranging from about 1.5 hours to about 5.5 hours. 
     
     
         60 . A method of treating cough, comprising administering the antitussive oral formulation of  claim 43  to the oral cavity of a patient in need thereof. 
     
     
         61 . An antitussive oral formulation comprising: memantine, or a pharmaceutically acceptable salt thereof; one or more excipients; and one or more additional pharmaceutically active ingredients selected from the group consisting of antitussives other than memantine, expectorants, mucolytics, decongestants, nasal decongestants, first generation antihistamines, antihistamines, opioid analgesics, non-opiate analgesics, and antipyretics.